Lin, Tara L. http://orcid.org/0000-0002-0242-6449
Newell, Laura F.
Stuart, Robert K.
Michaelis, Laura C.
Rubenstein, Eric
Pentikis, Helen S.
Callahan, Timothy
Alvarez, Donna
Liboiron, Barry D.
Mayer, Lawrence D.
Wang, Qi
Banerjee, Kamalika
Louie, Arthur C.
Funding for this research was provided by:
Celator Pharmaceuticals, Inc., a subsidiary of Jazz Pharmaceuticals, Inc.
Article History
Received: 3 April 2019
Accepted: 2 May 2019
First Online: 16 May 2019
Compliance with ethical standards
:
: TLL reports honoraria from Jazz; and advisory board participation for Pfizer. RKS reports honoraria, consulting, and travel support from Sunesis; and institutional research funding from Agios, Astellas, Bayer, Celator/Jazz, Incyte, and Sunesis. LCM reports research funding from Jazz; consulting and advisory board participation for Incyte, TG Therapeutics, Novartis, and Celgene; and stock ownership in Pfizer. ER reports speakers bureau participation for Alexion Pharmaceuticals and AstraZeneca; and advisory board participation for Celgene. HSP reports paid consultation for Celator/Jazz. TC reports employment at ERT. DA, BDL, LDM, and QW report employment at and stock ownership in Celator/Jazz. KB and ACL were former employees of Jazz, and ACL reports stock ownership in Celator/Jazz. LFN reports no potential conflicts of interest.
: This study was conducted according to the provisions of the Declaration of Helsinki and the International Conference on Harmonisation–Good Clinical Practice. The study protocol was approved by the institutional review board at each study site.
: All patients provided written informed consent before enrollment.